101 related articles for article (PubMed ID: 20857089)
21. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana.
Zhu HJ; Wang JS; Markowitz JS; Donovan JL; Gibson BB; Gefroh HA; Devane CL
J Pharmacol Exp Ther; 2006 May; 317(2):850-7. PubMed ID: 16439618
[TBL] [Abstract][Full Text] [Related]
22. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
Taub ME; Podila L; Ely D; Almeida I
Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
[TBL] [Abstract][Full Text] [Related]
23. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
24. Reversal of P-glycoprotein-mediated multidrug resistance in vitro by milbemycin compounds in adriamycin-resistant human breast carcinoma (MCF-7/adr) cells.
Xiang W; Gao A; Liang H; Li C; Gao J; Wang Q; Shuang B; Zhang J; Yan Y; Wang X
Toxicol In Vitro; 2010 Sep; 24(6):1474-81. PubMed ID: 20656007
[TBL] [Abstract][Full Text] [Related]
25. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672.
Elsby R; Gillen M; Butters C; Imisson G; Sharma P; Smith V; Surry DD
Drug Metab Dispos; 2011 Feb; 39(2):275-82. PubMed ID: 21075975
[TBL] [Abstract][Full Text] [Related]
26. Multi drug resistance-1 (MDR1) expression in response to chronic diazinon exposure: an in vitro study on Caco-2 cells.
Habibollahi P; Ghahremani MH; Azizi E; Ostad SN
Bull Environ Contam Toxicol; 2011 Jan; 86(1):105-9. PubMed ID: 21127835
[TBL] [Abstract][Full Text] [Related]
27. Thalidomide does not interact with P-glycoprotein.
Zimmermann C; Gutmann H; Drewe J
Cancer Chemother Pharmacol; 2006 May; 57(5):599-606. PubMed ID: 16136308
[TBL] [Abstract][Full Text] [Related]
28. The effect of fatty acids and analogues upon intracellular levels of doxorubicin in cells displaying P-glycoprotein mediated multidrug resistance.
Abulrob AN; Mason M; Bryce R; Gumbleton M
J Drug Target; 2000; 8(4):247-56. PubMed ID: 11144235
[TBL] [Abstract][Full Text] [Related]
29. Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay.
Döppenschmitt S; Langguth P; Regårdh CG; Andersson TB; Hilgendorf C; Spahn-Langguth H
J Pharmacol Exp Ther; 1999 Jan; 288(1):348-57. PubMed ID: 9862789
[TBL] [Abstract][Full Text] [Related]
30. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W
J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326
[TBL] [Abstract][Full Text] [Related]
31. Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR.
Tang XQ; Bi H; Feng JQ; Cao JG
Acta Pharmacol Sin; 2005 Aug; 26(8):1009-16. PubMed ID: 16038636
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC236) via inhibiting P-glycoprotein activity.
Yu L; Wu WK; Li ZJ; Liu QC; Li HT; Wu YC; Cho CH
Mol Pharmacol; 2009 Jun; 75(6):1364-73. PubMed ID: 19264847
[TBL] [Abstract][Full Text] [Related]
33. Effects of progesterone and leukotriene receptor antagonists in experimental models of P-glycoprotein-related resistance.
Nuessler V; Pelka-Fleischer R; Zwierzina H; Wilmanns W; Denzlinger C
Eur J Med Res; 1997 Apr; 2(4):159-64. PubMed ID: 9110922
[TBL] [Abstract][Full Text] [Related]
34. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
Newman MJ; Rodarte JC; Benbatoul KD; Romano SJ; Zhang C; Krane S; Moran EJ; Uyeda RT; Dixon R; Guns ES; Mayer LD
Cancer Res; 2000 Jun; 60(11):2964-72. PubMed ID: 10850444
[TBL] [Abstract][Full Text] [Related]
35. Colchicine effect on P-glycoprotein expression and activity: in silico and in vitro studies.
Silva R; Carmo H; Vilas-Boas V; Barbosa DJ; Palmeira A; Sousa E; Carvalho F; Bastos Mde L; Remião F
Chem Biol Interact; 2014 Jul; 218():50-62. PubMed ID: 24759273
[TBL] [Abstract][Full Text] [Related]
36. Effects of capsaicin on P-gp function and expression in Caco-2 cells.
Han Y; Tan TM; Lim LY
Biochem Pharmacol; 2006 Jun; 71(12):1727-34. PubMed ID: 16674925
[TBL] [Abstract][Full Text] [Related]
37. Caco-2/TC7 cell line characterization for intestinal absorption: how reliable is this in vitro model for the prediction of the oral dose fraction absorbed in human?
Turco L; Catone T; Caloni F; Di Consiglio E; Testai E; Stammati A
Toxicol In Vitro; 2011 Feb; 25(1):13-20. PubMed ID: 20732406
[TBL] [Abstract][Full Text] [Related]
38. P-glycoprotein expression induced by glucose depletion enhanced the chemosensitivity in human hepatocellular carcinoma cell-lines.
Cheng SC; Zhou J; Xie Y
Cell Biol Int; 2005 Apr; 29(4):269-75. PubMed ID: 15914037
[TBL] [Abstract][Full Text] [Related]
39. Effects of Schisandra lignans on P-glycoprotein-mediated drug efflux in human intestinal Caco-2.
Yoo HH; Lee M; Lee MW; Lim SY; Shin J; Kim DH
Planta Med; 2007 May; 73(5):444-50. PubMed ID: 17566147
[TBL] [Abstract][Full Text] [Related]
40. Selective downregulation of the MDR1 gene product in Caco-2 cells by stable transfection to prove its relevance in secretory drug transport.
Hilgendorf C; Spahn-Langguth H; Rhedin M; Regårdh CG; Löwenadler B; Langguth P
Mol Pharm; 2005; 2(1):64-73. PubMed ID: 15804179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
